Table 1.
Baseline characteristics of 16,010 NHANES III (1988–1994) participants stratified by eGFRMDRDand eGFRCKD-EPI
|
EGFRMDRD |
≥120 |
90-119 |
60-89 |
30-59 |
<30 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
(No. of participants)a |
(2,729) |
(6,604) |
(5,606) |
(1,015) |
(56) |
|||||||
| EGFRCKD-EPI | ≥120 | 90-119 | ≥120 | 90-119 | 60-89 | 90-119 | 60-89 | 30-59 | 60-89 | 30-59 | <30 | <30 |
| Number of participants a (%) b |
2,416 |
312 d |
1,473 |
4,969 |
162 |
1,870 |
3,664 |
72 |
120 |
883 |
12 |
55 e |
| (88.3) |
(11.7) |
(20.2) |
(78.4) |
(1.4) |
(42.9) |
(56.6) |
(0.5) |
(19.4) |
(79.5) |
(1.1) |
(99.5) |
|
|
Characteristicc |
|
|
|
|
|
|
|
|
|
|
|
|
| Serum Creatinine (mg/dl) |
0.64 |
0.59 |
0.76 |
0.79 |
0.70 |
0.87 |
0.94 |
1.07 |
1.07 |
1.26 |
1.97 |
2.76 |
| (0.004) |
(0.01) |
(0.003) |
(0.002) |
(0.01) |
(0.004) |
(0.004) |
(0.03) |
(0.02) |
(0.02) |
(0.11) |
(0.20) |
|
| EGFRMDRD (ml/min/1.73 m2) |
138 |
131 |
112 |
100 |
98 |
85 |
74 |
61 |
58 |
49 |
31 |
23 |
| (0.63) |
(0.72) |
(0.17) |
(0.18) |
(0.28) |
(0.09) |
(0.13) |
(0.09) |
(0.13) |
(0.27) |
(0.32) |
(0.88) |
|
| EGFRCKD-EPI (ml/min/1.73 m2) |
133 |
112 |
124 |
109 |
87 |
96 |
79 |
59 |
63 |
50 |
29 |
22 |
| (0.36) |
(0.51) |
(0.14) |
(0.12) |
(0.27) |
(0.18) |
(0.20) |
(0.13) |
(0.20) |
(0.30) |
(0.24) |
(0.92) |
|
| Age (years) |
26 (0.2) |
53 (0.8) |
28 (0.3) |
39 (0.2) |
79 (0.5) |
40 (0.5) |
59 (0.6) |
83 (1.0) |
56 (1.11) |
72 (0.74) |
81 (2.12) |
72 (1.75) |
| Age < 65 years, N (%) a b |
2,415 |
247 |
1,473 |
4,614 |
0 |
1,754 |
1,717 |
0 |
100 |
115 |
0 |
12 |
| (99.9) |
(85.8) |
(100) |
(96.4) |
|
(95.8) |
(61.3) |
|
(83.8) |
(18.0) |
|
(16.9) |
|
| Male (%) |
40 |
55 |
44 |
53 |
56 |
46 |
49 |
60 |
24 |
40 |
72 |
35 |
| Race/Ethnicity (%) |
|
|
|
|
|
|
|
|
|
|
|
|
| Non-Hispanic White |
52 |
67 |
65 |
74 |
85 |
86 |
86 |
86 |
90 |
86 |
90 |
73 |
| Non-Hispanic Black |
25 |
9 |
19 |
11 |
7 |
4 |
7 |
13 |
1 |
8 |
9 |
18 |
| Mexican American |
13 |
10 |
8 |
6 |
2 |
4 |
2 |
1 |
2 |
1 |
1 |
2 |
| Other |
11 |
13 |
9 |
10 |
7 |
6 |
6 |
1 |
6 |
5 |
0 |
8 |
| Ever or Current Smoker (%) |
45 |
68 |
46 |
56 |
47 |
51 |
54 |
43 |
57 |
55 |
84 |
56 |
| Diabetes (%) |
3 |
13 |
<1 |
3 |
11 |
3 |
8 |
6 |
14 |
15 |
27 |
26 |
| Prior CVD (%) |
<1 |
<1 |
<1 |
3 |
16 |
3 |
10 |
22 |
13 |
26 |
73 |
35 |
| Body Mass Index (kg/m2) |
25 |
27 |
25 |
26 |
25 |
26 |
27 |
25 |
29 |
28 |
25 |
26 |
| (0.23) |
(0.75) |
(0.20) |
(0.14) |
(0.26) |
(0.20) |
(0.15) |
(0.45) |
(0.68) |
(0.24) |
(1.02) |
(1.18) |
|
| Systolic Blood Pressure, mm Hg |
112 |
130 |
112 |
119 |
145 |
118 |
131 |
143 |
130 |
143 |
150 |
145 |
| (0.46) |
(1.90) |
(0.34) |
(0.31) |
(1.86) |
(0.45) |
(0.59) |
(1.99) |
(2.22) |
(1.03) |
(6.01) |
(3.66) |
|
| Diastolic Blood Pressure, mm Hg |
68 |
78 |
69 |
74 |
73 |
75 |
76 |
72 |
76 |
75 |
71 |
73 |
| (0.41) |
(0.95) |
(0.35) |
(0.28) |
(1.05) |
(0.32) |
(0.25) |
(1.14) |
(0.85) |
(0.49) |
(2.11) |
(2.98) |
|
| Antihypertensive medication use (%) |
4 |
26 |
2 |
10 |
32 |
10 |
27 |
44 |
36 |
60 |
75 |
74 |
| Total Cholesterol (mg/dl) |
183 |
217 |
181 |
198 |
208 |
204 |
217 |
213 |
230 |
232 |
209 |
230 |
| (1.69) |
(4.92) |
(1.68) |
(1.14) |
(3.82) |
(1.57) |
(1.21) |
(5.49) |
(4.65) |
(2.81) |
(10.31) |
(14.24) |
|
| CRP (mg/dl; %) |
|
|
|
|
|
|
|
|
|
|
|
|
| <0.22 |
73 |
58 |
80 |
75 |
71 |
76 |
67 |
62 |
64 |
52 |
29 |
42 |
| 0.22-0.99 |
19 |
29 |
14 |
19 |
22 |
19 |
25 |
28 |
23 |
32 |
12 |
40 |
| ≥1.00 |
9 |
13 |
6 |
6 |
7 |
5 |
8 |
10 |
13 |
16 |
59 |
18 |
| ACR (mg/g; %) |
|
|
|
|
|
|
|
|
|
|
|
|
| <30 |
93 |
84 |
93 |
94 |
74 |
95 |
89 |
78 |
83 |
70 |
9 |
34 |
| 30-300 |
6 |
11 |
7 |
5 |
25 |
5 |
10 |
18 |
15 |
23 |
68 |
20 |
| ≥300 | <1 | 5 | <1 | <1 | 17 | 1 | 1 | 4 | 3 | 7 | 23 | 46 |
Abbreviations: CVD, Cardiovascular Disease; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease Study; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CRP, C-reactive protein; ACR, albumin-to-creatinine ratio.
Note: Conversion factors for units: low- and high-density lipoprotein cholesterol in mg/dL to mmol/L, ×0.02586; triglycerides in mg/dL to mmol/L, ×0.01129; creatinine in mg/dL to μmol/L, ×88.4; eGFR in mL/min/1.73 m2 to mL/s/1.73 m2, ×0.01667; albumin-creatinine ratio in mg/g to mg/mmol, divide by 8.84.
a Participant numbers are unweighted N.
b Percent represents the population percent representative of the non-institutionalized US population; total may not equal 100% due to rounding.
c Values presented are population % for categorical variables and mean (linearized standard error) for continuous variables.
d One 86 year old Mexican-American female with serum creatinine = 0.488 mg/dL had eGFRMDRD = 120 ml/min/1.73 m2 and eGFRCKD-EPI 89 ml/min/1.73 m2 (data not shown).
e One 64 year old Mexican-American female with serum creatinine = 1.736 had eGFRMDRD = 29.5 ml/min/1.73 m2 and eGFRCKD-EPI = 30.6 ml/min/1.73 m2 (data not shown).